We’re developing a drug to slow down Parkinson's.
Andarta Therapeutics is a clinical-stage company using first-in-class inhibitors of fatty acid synthase (FASN) to slow the progression of Parkinson’s disease.
We’re developing a drug to slow down Parkinson's.
Andarta Therapeutics is a clinical-stage company using first-in-class inhibitors of fatty acid synthase (FASN) to slow the progression of Parkinson’s disease.
We’re developing a drug to slow down Parkinson's.
Andarta Therapeutics is a clinical-stage company using first-in-class inhibitors of fatty acid synthase (FASN) to slow the progression of Parkinson’s disease.
Parkinson’s is one of the fastest-growing neurological diseases worldwide. But there are currently no approved therapies that slow or stop the progression of Parkinson’s disease.
We’re developing a compound to change that.
Parkinson’s is one of the fastest-growing neurological diseases worldwide. But there are currently no approved therapies that slow or stop the progression of Parkinson’s disease.
We’re developing a compound to change that.
The number of people living with Parkinson’s is expected to double by 2050, with estimates suggesting up to 25 million individuals globally.
Scientific understanding of Parkinson’s disease has advanced rapidly in recent years. But existing treatments primarily address symptoms, leaving the underlying neurodegeneration unchecked.
Andarta Therapeutics is developing a novel therapeutic approach designed to address this unmet need.
The number of people living with Parkinson’s is expected to double by 2050, with estimates suggesting up to 25 million individuals globally.
Scientific understanding of Parkinson’s disease has advanced rapidly in recent years. But existing treatments primarily address symptoms, leaving the underlying neurodegeneration unchecked.
Andarta Therapeutics is developing a novel therapeutic approach designed to address this unmet need.
Treating Parkinson’s Disease Through a New Metabolic Lens
Our lead program, AND-0765, is being developed with the goal of slowing the progression of Parkinson’s disease, rather than simply managing symptoms.
AND-0765 is a first-in-class inhibitor of fatty acid synthase (FASN), a key enzyme involved in fatty acid metabolism. This program is grounded in a new and emerging scientific framework known as fattyacidopathy.
Treating Parkinson’s Disease Through a New Metabolic Lens
Our lead program, AND-0765, is being developed with the goal of slowing the progression of Parkinson’s disease rather than simply managing symptoms.
AND-0765 is a first-in-class inhibitor of fatty acid synthase (FASN), a key enzyme involved in fatty acid metabolism. This program is grounded in a new and emerging scientific framework known as fattyacidopathy.